Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL866662 | 1.00 | MEN1 (0.49) | MEN1KMT2ACYP3A4CYP1A2LMNA | |
| SCHEMBL866661 | 1.00 | MEN1 (0.49) | MEN1KMT2ACYP3A4CYP1A2LMNA | |
| SCHEMBL11959996 | 1.00 | MEN1 (0.49) | MEN1KMT2ACYP3A4CYP1A2LMNA | |
| SCHEMBL11960056 | 1.00 | MEN1 (0.49) | MEN1KMT2ACYP3A4CYP1A2LMNA | |
| SCHEMBL6897132 | 0.84 | MEN1 (0.42) | MEN1KMT2ACYP3A4CYP1A2NPC1 | |
| SCHEMBL6897130 | 0.84 | MEN1 (0.42) | MEN1KMT2ACYP3A4CYP1A2NPC1 | |
| SCHEMBL6449282 | 0.82 | CYP3A4 (0.55) | MEN1KMT2ACYP3A4NPC1RELA | |
| SCHEMBL6449288 | 0.82 | CYP3A4 (0.55) | MEN1KMT2ACYP3A4NPC1RELA | |
| SCHEMBL1853495 | 0.81 | CYP1A2 (0.46) | MEN1KMT2ACYP3A4CYP1A2LMNA | |
| SCHEMBL1853494 | 0.81 | CYP1A2 (0.46) | MEN1KMT2ACYP3A4CYP1A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251390-A1 | NICOTINE-BASED COMPOUNDS USEFUL FOR ASYMMETRIC SYNTHESIS | NORTH CAROLINA STATE UNIVERSITY | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251390-A1 | NICOTINE-BASED COMPOUNDS USEFUL FOR ASYMMETRIC SYNTHESIS | PNMT, NAPRT, PHOSPHO1 | MEN1 2094/4885KMT2A 1086/4885CYP3A4 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.